2021 American Transplant Congress
Donor-derived Cell-free DNA in Upper Extremity Vascular Composite Allograft Recipients
*Purpose: Diagnosing rejection in VCA recipients relies on clinical exam and biopsy which are both easily confounded by common causes of skin irritation. dd-cfDNA in…2021 American Transplant Congress
Donor-Derived Cell-Free DNA Performance Characteristics are Similar for Repeat and Primary Kidney Transplant Recipients
*Purpose: Repeat kidney transplants (RKT) represent 12.4% of kidney transplants (KT) (10.9% of all living donor and 13.6% of all deceased donor). Most RKT are…2021 American Transplant Congress
Nonadherence Post-kidney Transplant is Associated with Increased Immune Activation Detected by Peripheral Blood Gene Expression Assay
*Purpose: Nonadherence to immunosuppression medications is common post-transplantation. We hypothesize that nonadherence results in a heightened alloimmune response in kidney transplant recipients (KTRs) which in…2021 American Transplant Congress
Trugraf Gene Expression Testing Can Discriminate Rejection in the Setting of Acute Kidney Injury
*Purpose: The TruGraf kidney blood gene expression test is a well-validated non-invasive biomarker to detect immune quiescence thus ruling out silent subclinical rejection in stable…2021 American Transplant Congress
Comparison of Next Generation Sequencing Donor-derived Cell Free DNA Assay Utilizing Whole Genome Sequencing
*Purpose: Circulating donor-derived cell free DNA (dd-cfDNA) is a non-invasive biomarker of kidney allograft injury with a high negative predictive value for ruling out acute…2021 American Transplant Congress
Use of Microbial Cell Free DNA Sequencing in Solid Organ Transplant Patients
University of California, Los Angeles, Los Angeles, CA
*Purpose: Microbial cell free DNA (cfDNA) sequencing has emerged as a new noninvasive tool for the diagnosis of infectious diseases in recent years, but its…2021 American Transplant Congress
Clinical Validation and Performance of Donor-Derived Cell-Free DNA in Allograft Rejection
*Purpose: Extensive literature regarding the utility of donor-derived cell-free DNA (dd-cfDNA) shares various thresholds for active rejection (AR) based on differing data sets for both…2021 American Transplant Congress
Plasma Donor-Derived Cell-Free DNA Levels Risk-Stratify Kidney Allograft Injury with Isolated Transplant Glomerulitis
*Purpose: The Banff lesion Glomerulitis (g) characterizes the degree of microvascular glomerular inflammation. Some studies have demonstrated glomerulitis in the absence of C4d in association…2021 American Transplant Congress
A Noninvasive Diagnostic Approach for Molecular Monitoring of Face Transplant Recipients
*Purpose: Skin biopsies are currently the gold standard for evaluating the inflammatory status of face allografts. However, “tape stripping” is emerging as a noninvasive technique…2021 American Transplant Congress
Donor-Derived Cell-Free DNA as a Surrogate Marker for “Allograft Quiescence” After Kidney Transplantation
*Purpose: Donor-derived cell-free DNA (dd-cfDNA; AlloSure®) and the association with active rejection (AR) was described by Bloom et al, however subsequent insights have suggested this…
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- …
- 10
- Next Page »